Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients-Reference-Cited by-同舟云学术

Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients

Published:2014-10 Issue:10 Volume:20 Page:621-626
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Zhu Liqin^ORCID,Wang Nan,Yang Wenjie,Zhang Yuan,Zhao Xuequn,Ji Shuangmin

Funder

Public Health Bureau

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Reference23 articles.

1. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP);Ferrara;Clin Interv Aging,2007

2. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD;Miravitlles;Int J Chron Obstruct Pulmon Dis,2007

3. In vitro activity of BAY 12-8039, a neu 8-methoxyquinolone;Dalhoff;Chemotherapy,1996

4. In vitro and in vivo activity of BAY 12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice;Rouse,1996

5. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study;Khan;AJR – Am J Roentgenol,2011

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Moxifloxacin loaded nanoparticles of disulfide bridged thiolated chitosan-eudragit RS100 for controlled drug delivery;International Journal of Biological Macromolecules;2021-07

2. Spectroscopic properties, molecular structure, anticancer and antimicrobial evaluation of some new moxifloxacin metal complexes in the presence of 1,10-phenanthroline;Bulletin of the Chemical Society of Ethiopia;2020-10-28

3. A pharmacometric approach to define target site-specific breakpoints for bacterial killing and resistance suppression integrating microdialysis, time–kill curves and heteroresistance data: a case study with moxifloxacin;Clinical Microbiology and Infection;2020-09

4. The Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid Following Intravenous Administration;Pediatric Infectious Disease Journal;2020-04-02

5. Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin;CPT: Pharmacometrics & Systems Pharmacology;2019-08-07